Dll3 Expressing Tumors clinical trials

Explore recruiting dll3 expressing tumors clinical trials.

Recruiting dll3 expressing tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dll3 Expressing Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Dll3 Expressing Tumors trials by city

Dll3 Expressing Tumors in Toronto Dll3 Expressing Tumors in Vancouver Dll3 Expressing Tumors in Montreal Dll3 Expressing Tumors in Calgary Dll3 Expressing Tumors in Edmonton Dll3 Expressing Tumors in Ottawa Dll3 Expressing Tumors in Winnipeg Dll3 Expressing Tumors in Quebec City Dll3 Expressing Tumors in Hamilton Dll3 Expressing Tumors in Kitchener Dll3 Expressing Tumors in London Dll3 Expressing Tumors in Halifax Dll3 Expressing Tumors in New York Dll3 Expressing Tumors in Los Angeles Dll3 Expressing Tumors in Chicago Dll3 Expressing Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease